Cocrystal Pharma Enters Material Agreement, Discloses Equity Sales
Ticker: COCP · Form: 8-K · Filed: Sep 15, 2025 · CIK: 1412486
| Field | Detail |
|---|---|
| Company | Cocrystal Pharma, INC. (COCP) |
| Form Type | 8-K |
| Filed Date | Sep 15, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $1.70, $1.50, $4.75 million, $2.125 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, disclosure
TL;DR
Cocrystal Pharma signed a big deal and sold some stock.
AI Summary
Cocrystal Pharma, Inc. announced on September 12, 2025, the entry into a material definitive agreement. The company also disclosed unregistered sales of equity securities and provided a Regulation FD disclosure. The filing includes financial statements and exhibits.
Why It Matters
This filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — The disclosure of unregistered equity sales can sometimes indicate financing needs or dilution concerns, while a material definitive agreement suggests significant business developments that carry inherent risks.
Key Players & Entities
- Cocrystal Pharma, Inc. (company) — Registrant
- September 12, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 19805 N. Creek Parkway (address) — Principal business address
- Bothell, WA (location) — Principal business address city and state
- 98011 (zip_code) — Principal business address zip code
FAQ
What is the nature of the material definitive agreement entered into by Cocrystal Pharma, Inc.?
The filing states that Cocrystal Pharma, Inc. entered into a material definitive agreement on September 12, 2025, but the specific details of the agreement are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 12, 2025.
What are the main items disclosed in this 8-K filing?
This 8-K filing discloses the entry into a material definitive agreement, unregistered sales of equity securities, a Regulation FD disclosure, and financial statements and exhibits.
Where is Cocrystal Pharma, Inc. headquartered?
Cocrystal Pharma, Inc.'s principal business address is located at 19805 N. Creek Parkway, Bothell, WA 98011.
What is the SEC file number for Cocrystal Pharma, Inc.?
The SEC file number for Cocrystal Pharma, Inc. is 001-38418.
Filing Stats: 1,418 words · 6 min read · ~5 pages · Grade level 11.3 · Accepted 2025-09-15 16:35:33
Key Financial Figures
- $0.001 — f the Company's common stock, par value $0.001 per share (the "Common Stock"), at a pr
- $1.70 — are (the "Common Stock"), at a price of $1.70 per share (the "Registered Direct Offer
- $1.50 — ants"), at an initial exercise price of $1.50 per share (the "Private Placement" and
- $4.75 million — raising gross proceeds of approximately $4.75 million before deducting placement agent fees a
- $2.125 — rice of the Placement Agent Warrants is $2.125 per share and have a term of exercise e
Filing Documents
- form8-k.htm (8-K) — 53KB
- ex4-1.htm (EX-4.1) — 115KB
- ex4-2.htm (EX-4.2) — 115KB
- ex5-1.htm (EX-5.1) — 13KB
- ex10-1.htm (EX-10.1) — 279KB
- ex99-2.htm (EX-99.2) — 13KB
- 0001493152-25-013495.txt ( ) — 872KB
- cocp-20250912.xsd (EX-101.SCH) — 3KB
- cocp-20250912_lab.xml (EX-101.LAB) — 33KB
- cocp-20250912_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cocrystal Pharma, Inc. Date: September 15, 2025 By: /s/ James Martin Name: James Martin Title: Chief Financial Officer and Co-Chief Executive Officer 4